Guillaume Carita

Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target

Nabil Amirouchene-Angelozzi, Fariba Némati, David Gentien et al. · Molecular Oncology · 2014 · 180 citations · Full text

Medicine, Molecular Biology, Oncology +17

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Guillaume Carita, Estelle Frisch-Dit-Leitz, Ahmed Dahmani et al. · Oncotarget · 2016 · 56 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts

Fariba Némati, Catherine de Montrion, Guillaume Lang et al. · PLoS ONE · 2014 · 49 citations · Full text

Medicine, Oncology, Pharmacology +17

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma

Nabil Amirouchene-Angelozzi, Estelle Frisch-Dit-Leitz, Guillaume Carita et al. · Oncotarget · 2016 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma

Leanne de Koning, Didier Decaudin, Rania El Botty et al. · Cancers · 2019 · 42 citations · Full text

Life Sciences, Molecular Biology, Oncology +17